Antiadrenergic effect of chronic amiodarone therapy in human heart failure

Journal of the American College of Cardiology

Volumn 33, Issue 6, 1999, Pages 1553-1559

  Kaye, David M ^a   Dart, Anthony M ^a   Jennings, Garry L ^a   Esler, Murray D ^a  

^a BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENERGIC RECEPTOR BLOCKING AGENT; AMIODARONE;

ADULT; ARTICLE; CONGESTIVE HEART FAILURE; DRUG EFFECT; HEART HEMODYNAMICS; HEART INNERVATION; HEART LEFT VENTRICLE FUNCTION; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; SYMPATHETIC INNERVATION;

ADRENERGIC ANTAGONISTS; ADULT; AGED; AMIODARONE; ANTI-ARRHYTHMIA AGENTS; CATECHOLAMINES; FEMALE; HEART FAILURE, CONGESTIVE; HEMODYNAMIC PROCESSES; HUMANS; MALE; MIDDLE AGED; SYMPATHETIC NERVOUS SYSTEM; TREATMENT OUTCOME; VENTRICULAR FUNCTION, LEFT;

EID: 0033133393     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(99)00042-X     Document Type: Article

References (35)

1. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study. N Engl J Med 1987; 316:1429-35.
2. The SOLVD Investigators. Effect of angiotensin converting enzyme inhibition with enalapril on survival in patients with reduced left ventricular ejection fraction and congestive heart failure: results of the Treatment Trial of the Studies of Left Ventricular Dysfunction (SOLVD): a randomized double blind trial. N Engl J Med 1991;325: 293-302.
3. Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 1996;334:1349-55.
4. The Cardiac Arrhythmia Suppression Trial (CAST) Investigators. Preliminary report: effect of encainide and flecanide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med 1992;327:227-33.
5. Doval HC, Nul DR, Grancelli HO, et al. Randomised trial of low-dose amiodarone in severe congestive heart failure. Lancet 1994; 344:493-8.
6. Singh SN, Fletcher RD, Gross-Fisher S, et al. Amiodarone in patients with congestive heart failure and asymptomatic ventricular tachycardia. N Engl J Med 1995;333:77-82.
7. Naccarelli GV, Dougherty AH. Amiodarone: a review of its pharmacologic, antiarrhythmic, and adverse effects. In: Podrid PJ, Kowey PR, editors. Cardiac Arrhythmia: Mechanisms, Diagnosis, and Management. Baltimore: Williams and Wilkins, 1995:434-49.
8. Shelson RS, Hill RJ, Cannon NJ, Duff HJ. Amiodarone: biochemical evidence for binding to a receptor for class I drugs associated with the rat cardiac sodium channel. Circ Res 1989;65:477-82.
9. Nattel S, Talajic M, Quantz M, DeRoode M. Frequency-dependent effects of amiodarone on AV nodal function and slow channel action potentials: evidence for calcium blocking activity. Circulation 1987;76: 442-9.
10. Bacq ZM, Blakely GH, Summers RH. The effects of amiodarone, an α and β receptor antagonist, on adrenergic transmission in the cat spleen. Biochem Pharmacol 1976;25:1195-9.
11. Du XJ, Esler MD, Dart AM. Sympatholytic action of intravenous amiodarone in the rat heart. Circulation 1995;91:462-70.
12. Hasking GJ, Esler MD, Jennings GL, et al. Norepinephrine spillover to plasma in patients with congestive heart failure: evidence of increased overall and cardiorenal sympathetic nervous activity. Circulation 1986;73:615-21.
13. Kaye DM, Lambert GW, Lefkovits J, et al. Neurochemical evidence of cardiac sympathetic activation and increased central nervous system norepinephrine turnover in severe congestive heart failure. J Am Coll Cardiol 1994;23:570-8.
14. Rundqvist B, Elam M, Bergmann-Sverrisdottir Y, et al. Increased cardiac adrenergic drive precedes generalized sympathetic activation in human heart failure. Circulation 1997;95:169-75.
15. Kaye DM, Lefkovits J, Jennings G, et al. Adverse consequences of increased cardiac sympathetic activity in the failing human heart. J Am Coll Cardiol 1995;26:1257-63.
16. Bristow MR, Gilbert EM, Abraham WT, et al. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. Circulation 1996;94:2807-16.
17. Ganz W, Tamura K, Marcus H, et al. Measurement of coronary sinus blood flow by continuous thermodilution in man. Circulation 1971; 44:181-95.
18. Esler M, Jackman G, Bobik A, et al. Determination of norepinephrine apparent release rate and clearance in humans. Life Sci 1979;25:1461-70.
19. Esler M, Jennings G, Lambert G, et al. Overflow of catecholamine neurotransmitters to the circulation: source, fate, and functions. Physiol Rev 1990;70:963-85.
20. Esler M, Jennings G, Korner P, et al. Measurement of total and organ-specific norepinephrine kinetics in humans. Am J Physiol 1984;247:E21-8.21.
21. Medvedev OS, Esler MD, Angus JA, et al. Simultaneous determination of plasma noradrenaline and adrenaline kinetics. Response to nitroprusside-induced hypotension and 2-deoxyglucose-induced glucopenia in the rabbit. Naunyn Schmiedeberg Arch Pharmacol 1990; 341:192-9.
22. Cohn J, Levine T, Olivari M, et al. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med 1984;311:819-23.
23. Schwartz PJ, Billman GE, Stone HL. Autonomic mechanisms in ventricular fibrillation induced by myocardial ischemia during exercise in dogs with healed myocardial infarction. Circulation 1984;69:790-800.
24. Mann DL, Kent RL, Parsons B, Cooper G. Adrenergic effects on the biology of the adult mammalian cardiocyte. Circulation 1992;85:790-804.
25. Bristow MR, Ginsberg R, Umans V, et al. β1- and β2-adrenergic receptor subpopulations in nonfailing and failing human ventricular myocardium: coupling of both receptor subtypes to muscle contraction and selective β1 receptor down-regulation in heart failure. Circ Res 1986;59:297-309.
26. Bristow MR, Anderson FL, Port DJ, et al. Differences in β-adrenergic neuroeffector mechanisms in ischemic versus idiopathic dilated cardiomyopathy. Circulation 1991;84:1024-39.
27. Gilbert EM, Abraham WT, Olsen S, et al. Comparative hemodynamic, left ventricular functional, and antiadrenergic effects of chronic treatment with metoprolol versus carvedilol in the failing heart. Circulation 1996;94:2817-25.
28. Charlier R. Cardiac actions in the dog of a new antagonist of adrenergic excitation which does not produce competitive blockade of adrenoceptors. Br J Pharmacol 1970;39:668-74.
29. Zigmond RE, Scwarzschild MA, Rittenhouse AR. Acute regulation of tyrosine hydroxylase activity by nerve activity and neurotransmitters via phosphorylation. Ann Rev Neurosci 1989;12:415-61.
30. Eisenhofer G, Meredith IT, Ferrier C, et al. Increased plasma dihydroxyphenylalanine during sympathetic activation in humans is related to increased norepinephrine turnover. J Lab Clin Med 1991; 117:266-73.
31. Ferguson DW, Berg WJ, Sanders JS. Clinical and hemodynamic correlates of sympathetic neural activity in normal humans and patients with heart failure - evidence from direct microneurographic recordings. J Am Coll Cardiol 1990;16:1125-34.
32. Meredith IT, Eisenhofer G, Lambert GW, et al. Cardiac sympathetic nervous activity in congestive heart failure: evidence for increased neuronal norepinephrine release and preserved neuronal uptake. Circulation 1993;88:136-45.
33. Nul DR, Doval HC, Grancelli HO, et al. Heart rate is a marker of amiodarone mortality reduction in severe heart failure. J Am Coll Cardiol 1997;29:1199-205.
34. Kaye DM, Jennings GL, Dart AM, Esler MD. Differential effect of acute baroreceptor unloading on cardiac and systemic sympathetic tone in congestive heart failure. J Am Coll Cardiol 1998;31:583-7.
35. Haikerwal D, Dart A, Kaye DM. Identification of a novel inhibitory action of amiodarone on vesicular monoamine transport. J Pharmacol Exp Ther 1999;288:834-7.